MoonLake Immunotherapeutics - Class A Ordinary Shares (MLTX)
10.10
+0.29 (2.96%)
NASDAQ · Last Trade: Oct 31st, 4:46 PM EDT
Detailed Quote
| Previous Close | 9.810 | 
|---|---|
| Open | 9.830 | 
| Bid | 10.00 | 
| Ask | 10.10 | 
| Day's Range | 9.700 - 10.13 | 
| 52 Week Range | 5.950 - 62.75 | 
| Volume | 2,161,928 | 
| Market Cap | - | 
| PE Ratio (TTM) | -3.633 | 
| EPS (TTM) | -2.8 | 
| Dividend & Yield | N/A (N/A) | 
| 1 Month Average Volume | 7,671,283 | 
Chart
About MoonLake Immunotherapeutics - Class A Ordinary Shares (MLTX)
MoonLake Immunotherapeutics is a biopharmaceutical company focused on developing novel therapeutics for the treatment of autoimmune and inflammatory diseases. Leveraging its advanced proprietary platform, the company works on innovative approaches to enhance patient outcomes and address unmet medical needs in this therapeutic area. By integrating cutting-edge research and development strategies, MoonLake aims to bring new treatment options to market that can significantly improve the quality of life for individuals affected by chronic diseases. Their commitment to science and patient care drives their mission to transform the landscape of immunotherapy. Read More
News & Press Releases
LOS ANGELES, Oct.  31, 2025  (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
By Schall Law · Via GlobeNewswire · October 31, 2025
Search for the latest press releases from  publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · October 31, 2025
NEW YORK - October 31, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics (NASDAQ: MLTX) of a class action securities lawsuit.
Via TheNewswire.com · October 31, 2025
NEW YORK, Oct.  31, 2025  (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of aTyr Pharma, Inc. (NASDAQ:ATYR), Marex Group PLC (NASDAQ:MRX), Cepton, Inc. (NASDAQ:CPTN), and MoonLake Immunotherapeutics (NASDAQ:MLTX). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
By Bragar Eagel & Squire · Via GlobeNewswire · October 31, 2025
Glancy Prongay & Murray LLP reminds investors of the upcoming December 15, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) common stock between March 10, 2024 and September 29, 2025, inclusive (the “Class Period”).
By Glancy Prongay & Murray LLP · Via Business Wire · October 30, 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their Options
By Faruqi & Faruqi LLP · Via GlobeNewswire · October 30, 2025
NEW YORK, Oct.  30, 2025  (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against MoonLake Immunotherapeutics (“Moonlake” or the “Company”) (NASDAQ: MLTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
By Pomerantz LLP · Via GlobeNewswire · October 30, 2025
Search for the latest press releases from  publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · October 30, 2025
NEW YORK - October 30, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics (NASDAQ: MLTX) of a class action securities lawsuit.
Via TheNewswire.com · October 30, 2025
NEW YORK, Oct.  30, 2025  (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
By Bernstein Liebhard LLP · Via GlobeNewswire · October 30, 2025
Law Offices of Howard G. Smith reminds investors of the upcoming December 15, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) common stock between March 10, 2024 and September 29, 2025, inclusive (the “Class Period”).
By Law Offices of Howard G. Smith · Via Business Wire · October 29, 2025
NEW YORK - October 29, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics (NASDAQ: MLTX) of a class action securities lawsuit.
Via TheNewswire.com · October 29, 2025
Search for the latest press releases from  publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · October 29, 2025
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) common stock between March 10, 2024 and September 29, 2025, inclusive (the “Class Period”). MoonLake investors have until December 15, 2025 to file a lead plaintiff motion.
By Law Offices of Frank R. Cruz · Via Business Wire · October 28, 2025
LOS ANGELES, Oct.  28, 2025  (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
By Schall Law · Via GlobeNewswire · October 28, 2025
Search for the latest press releases from  publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · October 28, 2025
NEW YORK - October 28, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics (NASDAQ: MLTX) of a class action securities lawsuit.
Via TheNewswire.com · October 28, 2025
NEW YORK, Oct.  27, 2025  (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of aTyr Pharma, Inc. (NASDAQ:ATYR), Marex Group PLC (NASDAQ:MRX), Cepton, Inc. (NASDAQ:CPTN), and MoonLake Immunotherapeutics (NASDAQ:MLTX). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
By Bragar Eagel & Squire · Via GlobeNewswire · October 27, 2025
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) common stock between March 10, 2024 and September 29, 2025, inclusive (the “Class Period”). MoonLake investors have until December 15, 2025 to file a lead plaintiff motion.
By Glancy Prongay & Murray LLP · Via Business Wire · October 27, 2025
NEW YORK, Oct.  27, 2025  (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
By Bernstein Liebhard LLP · Via GlobeNewswire · October 27, 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In MoonLake To Contact Him Directly To Discuss Their Options
By Faruqi & Faruqi LLP · Via GlobeNewswire · October 26, 2025
NEW YORK, Oct.  25, 2025  (GLOBE NEWSWIRE) -- 
By The Rosen Law Firm PA · Via GlobeNewswire · October 25, 2025
NEW YORK - October 24, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics (NASDAQ: MLTX) of a class action securities lawsuit.
Via TheNewswire.com · October 24, 2025
Search for the latest press releases from  publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · October 24, 2025
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) common stock between March 10, 2024 and September 29, 2025, inclusive (the “Class Period”). MoonLake investors have until December 15, 2025 to file a lead plaintiff motion.
By Law Offices of Howard G. Smith · Via Business Wire · October 24, 2025